相关临床试验
1
0 进行中
药物批准
28
批准总数
监管机构
1
监管机构数
成立时间
N/A
招募中
1
100.0%
- Precipio (PRPO) combines clinical laboratory services with proprietary diagnostic product development, with pathology services focused primarily on hematologic cancers. - Biodesix (BDSX) provides blood-based diagnostic testing for lung disease, including tests that assess cancer risk in lung nodules and guide post-diagnosis treatment. - Biodesix has outperformed Precipio over the past three months (up 64.5% vs. 26.4%) and over the past year (up 150.9% vs. 112%). - Both stocks trade below the Zacks Medical sector average EV/S of 2.92X, with PRPO at 1.90X and BDSX at 2.89X.
- The global urinalysis market is projected to grow from USD 4.88 billion in 2026 to USD 7.16 billion by 2031, at a compound annual growth rate (CAGR) of 8.0%. - The consumables segment held the largest market share at 72.5% in 2025, while pregnancy and fertility tests led test types with a 42.8% share. - North America remains the largest regional market, with Asia Pacific expected to register the fastest growth during the forecast period. - Growth is driven by rising prevalence of urinary tract infections, diabetes, and kidney and liver diseases, alongside increasing adoption of automated and point-of-care testing.
- The radioligand therapy market was valued at USD 2.98 billion in 2025 and is forecast to reach USD 15.85 billion by 2035, an 18.2% CAGR. - Novartis received expanded FDA approval in 2026 for Pluvicto in earlier-line metastatic castration-resistant prostate cancer, moving PSMA therapy ahead of chemotherapy. - Eli Lilly advanced 177Lu-PNT2002 into a pivotal Phase 3 trial in biochemically recurrent prostate cancer, while Convergent Therapeutics began Phase III testing of CONV01-alpha. - Alpha-emitter pipeline agents using actinium-225 and lead-212 are the fastest-growing product segment, projected at a 24.6% CAGR through 2035.
- WindRose Health Investors has completed the recapitalization of Verified Clinical Trials (VCT), a global leader in clinical trial subject registry solutions. - Howard Miller, former CEO of Envision Pharma Group, has been appointed as VCT's new Chief Executive Officer to lead the next phase of growth. - Co-founders Mitchell Efros, MD, and Kerri Weingard, ANP, will remain actively involved, transitioning to roles focused on long-term strategy and client relationships. - The investment aims to expand VCT's data and analytics capabilities, infrastructure, and geographic reach to better serve pharmaceutical sponsors, CROs, and clinical trial sites.
- The FDA classified a nationwide recall of levothyroxine sodium tablets as Class II on July 17 after routine stability testing found the tablets were subpotent, meaning they contain less active drug than labeled. - The recall, initiated by manufacturer Lupin Pharmaceuticals and distributed by Major Pharmaceuticals and Cardinal Health, covers seven strengths (25–150 mcg) across 12 products with expiration dates extending to January 2027. - Patients are advised to continue taking their medication, as stopping a recalled drug can cause more harm than continuing, and pharmacies are not required to notify patients directly. - Experts note the recall demonstrates the system working as intended, with routine monitoring and blood tests allowing clinicians to detect low thyroid function before significant adverse effects occur.
- The CMS Acute Hospital Care at Home (AHCAH) initiative has been extended by Congress until September 2030, giving healthcare providers a multiyear window to expand home-based inpatient care programs. - Studies show hospital-at-home care is associated with lower Medicare spending in the 30-day post-discharge period and lower mortality rates compared to traditional inpatient stays. - Key benefits include avoidance of hospital-acquired infections, reduced mobility decline and delirium, lower caregiver strain, and better outcomes from familiar patient settings. - Significant challenges remain, including infrastructure requirements, workforce availability, cybersecurity risks, and the need for robust data governance frameworks to protect patient information.
- Ember LifeSciences raised $27 million in Series A funding with strategic investments from Amgen Ventures and TDF Ventures to scale its cold chain logistics platform. - The company launched commercial availability of the Ember Cube 2, an award-winning reusable shipping solution designed to address billions of dollars in annual pharmaceutical losses from temperature excursions. - Existing customers include major pharmaceutical distributors CVS Health, Cardinal Health, Chartwell and USADA, positioning the company to expand its global footprint in healthcare delivery.
- AMR Bio has launched as a clinical-phase biotechnology company to advance XF-73, a first-in-class topical antimicrobial gel designed to prevent post-surgical infections. - The lead product XF-73 Nasal demonstrated a 99.5% reduction in bacterial nasal carriage in a Phase IIb trial of 124 patients undergoing open heart surgery. - Post-surgical infections cost approximately $10 billion annually in the US, while antimicrobial resistance contributes to nearly five million deaths each year globally. - The company has secured regulatory advantages including FDA Fast Track status and UK MHRA Innovation Passport for accelerated market access.
- Cardinal Health reported an enormous revenue base of $250.7 billion, providing significant economies of scale and competitive advantages in the complex pharmaceutical distribution industry. - The company's forecasted revenue growth of 8.1% over the next 12 months signals stronger momentum compared to most industry peers. - Annual earnings per share growth of 12.4% over the past five years has outpaced revenue gains, driven in part by share repurchase programs. - Cardinal Health shares are currently trading at $229.84, representing a forward price-to-earnings ratio of 19.7x.
- Ember LifeSciences secured $16.5 million in Series A funding led by Sea Court Capital to advance cold chain technology for pharmaceutical distribution. - The global pharmaceutical cold chain ecosystem loses $35 billion annually due to temperature excursions and generates 330 billion pounds of waste from single-use packaging. - The funding will support the launch of Ember Cube 2, featuring vacuum insulation and bio-based phase change materials for temperature-sensitive therapies. - Leading healthcare organizations including CVS Health, Chartwell, and USADA are already adopting Ember LifeSciences' cold chain technology.
